SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

Home・Listă Acțiuni・Pharma Mar SA

P
Pharma Mar SA

Deschisă

99 5.54

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

92.15

Maxim

98.8

Indicatori cheie
By Trading Economics
Venit	-58M 1.6M
Vânzări	-48M 43M
P/E Medie Sector	21.191 49.888
EPS	0.088
Marjă de profit	3.725
Angajați	505
EBITDA	-40M 2.7M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+27.25% upside

Dividende
By Dow Jones
Următoarele câștiguri	29 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	40M 1.7B
Deschiderea anterioară	93.46
Închiderea anterioară	99

Pharma Mar SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 iun. 2026, 21:51 UTC

Principalele dinamici ale pieței

Merlin Shares Rally After Defense Department's Design Review Wraps

4 iun. 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 iun. 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 iun. 2026, 23:42 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 iun. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia to Enter Trading Halt

4 iun. 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 iun. 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 iun. 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 20:44 UTC

Achiziții, Fuziuni, Preluări

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 iun. 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 iun. 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 iun. 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 iun. 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 iun. 2026, 18:47 UTC

Achiziții, Fuziuni, Preluări

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 iun. 2026, 18:38 UTC

Câștiguri

Money Quote: Tech Weakness in Context -- WSJ

4 iun. 2026, 18:24 UTC

Câștiguri

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 iun. 2026, 16:58 UTC

Câștiguri

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 iun. 2026, 16:38 UTC

Câștiguri

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 iun. 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 iun. 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 iun. 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparație

Modificare preț

Pharma Mar SA Așteptări

Obiectiv de preț

By TipRanks

27.25% sus

Prognoză pe 12 luni

Medie 120.502 EUR 27.25%

Maxim 121 EUR

Minim 120 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPharma Mar SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Pharma Mar SA - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.